Surjit Pal, analyst(pharma sector) at Prabhudas Lilladher told NDTV that although Lupin's Q4 earnings were disappointing on all fronts but he does not expect much downside in the stock as it has some limited competition niche products which has revenue visibility for the next two years. Correction if any in the stock will be in-line with the top players in the industry, added Mr Pal.
